# Rebecca C Fitzgerald

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 199 papers | 10,111 citations | 55 h-index | 96 g-index |
| 225 ext. papers | 13,123 ext. citations | 12.1 avg, IF | 6.18 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 199 | British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. *Gut*, **2014**, 63, 7-42 | 19.2 | 863 |
| 198 | Somatic mutant clones colonize the human esophagus with age. *Science*, **2018**, 362, 911-917 | 33.3 | 465 |
| 197 | Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. *Journal of Medical Genetics*, **2015**, 52, 361-74 | 5.8 | 385 |
| 196 | Oesophageal cancer. *Nature Reviews Disease Primers*, **2017**, 3, 17048 | 51.1 | 367 |
| 195 | Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. *Journal of Clinical Investigation*, **1996**, 98, 2120-8 | 15.9 | 258 |
| 194 | Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. *Nature Genetics*, **2014**, 46, 837-843 | 36.3 | 240 |
| 193 | Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. *Nature Genetics*, **2016**, 48, 1131-41 | 36.3 | 233 |
| 192 | Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. *BMJ, The*, **2010**, 341, c4372 | 5.9 | 232 |
| 191 | Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus. *Nature Medicine*, **2012**, 18, 315-21 | 50.5 | 221 |
| 190 | The landscape of somatic mutation in normal colorectal epithelial cells. *Nature*, **2019**, 574, 532-537 | 50.4 | 217 |
| 189 | Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. *Gut*, **2002**, 50, 451-9 | 19.2 | 196 |
| 188 | Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. *Nature Genetics*, **2015**, 47, 1038-1046 | 36.3 | 190 |
| 187 | Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett's esophagus: a multi-center case-control study. *PLoS Medicine*, **2015**, 12, e1001780 | 11.6 | 162 |
| 186 | scRNA-seq assessment of the human lung, spleen, and esophagus tissue stability after cold preservation. *Genome Biology*, **2019**, 21, 1 | 18.3 | 161 |
| 185 | A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. *Nature Genetics*, **2013**, 45, 1487-93 | 36.3 | 151 |
| 184 | History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. *Gastroenterology*, **2010**, 138, 854-69 | 13.3 | 148 |
| 183 | Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus. *Gastroenterology*, **2013**, 144, 62-73.e6 | 13.3 | 128 |

| | | | |
|---|---|---|---|
| 182 | Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. *Lancet, The*, **2018**, 392, 400-408 | 40 | 127 |
| 181 | Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus. *Gastroenterology*, **2012**, 143, 927-35.e3 | 13.3 | 127 |
| 180 | Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. *Nature Genetics*, **2020**, 52, 306-319 | 36.3 | 122 |
| 179 | Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 2177-82 | 11.5 | 122 |
| 178 | A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. *Gastroenterology*, **2010**, 139, 1995-2004.e15 | 13.3 | 116 |
| 177 | Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics. *Nature Communications*, **2018**, 9, 2983 | 17.4 | 113 |
| 176 | Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. *Journal of Pathology*, **2008**, 216, 295-306 | 9.4 | 105 |
| 175 | Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. *Gut*, **2006**, 55, 1810-20 | 19.2 | 103 |
| 174 | Precision prevention of oesophageal adenocarcinoma. *Nature Reviews Gastroenterology and Hepatology*, **2015**, 12, 243-8 | 24.2 | 101 |
| 173 | Endoscopic Management of Early Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus: Screening, Diagnosis, and Therapy. *Gastroenterology*, **2018**, 154, 421-436 | 13.3 | 101 |
| 172 | Screening for oesophageal cancer. *Nature Reviews Clinical Oncology*, **2012**, 9, 278-87 | 19.4 | 95 |
| 171 | Hereditary diffuse gastric cancer: updated clinical practice guidelines. *Lancet Oncology, The*, **2020**, 21, e386-e397 | 21.7 | 95 |
| 170 | Accuracy, safety, and tolerability of tissue collection by Cytosponge vs endoscopy for evaluation of eosinophilic esophagitis. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 77-83.e2 | 6.9 | 94 |
| 169 | Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. *Lancet Oncology, The*, **2016**, 17, 1363-1373 | 21.7 | 94 |
| 168 | Histopathological and molecular analysis of gastrectomy specimens from hereditary diffuse gastric cancer patients has implications for endoscopic surveillance of individuals at risk. *Journal of Pathology*, **2008**, 216, 286-94 | 9.4 | 94 |
| 167 | International cancer seminars: a focus on esophageal squamous cell carcinoma. *Annals of Oncology*, **2017**, 28, 2086-2093 | 10.3 | 93 |
| 166 | A review of the current understanding and clinical utility of miRNAs in esophageal cancer. *Seminars in Cancer Biology*, **2013**, 23, 512-21 | 12.7 | 93 |
| 165 | Randomized crossover study comparing efficacy of transnasal endoscopy with that of standard endoscopy to detect Barrett's esophagus. *Gastrointestinal Endoscopy*, **2012**, 75, 954-61 | 5.2 | 91 |

| | | | |
|---|---|---|---|
| 164 | Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic. *Gut*, **2009**, 58, 1451-9 | 19.2 | 91 |
| 163 | Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus. *Digestive Diseases and Sciences*, **2001**, 46, 1892-8 | 4 | 90 |
| 162 | The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. *Nature Genetics*, **2019**, 51, 506-516 | 36.3 | 86 |
| 161 | Nitric oxide and acid induce double-strand DNA breaks in Barrett's esophagus carcinogenesis via distinct mechanisms. *Gastroenterology*, **2007**, 133, 1198-209 | 13.3 | 81 |
| 160 | Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett's esophagus. *Gastroenterology*, **2015**, 148, 367-78 | 13.3 | 76 |
| 159 | A non-endoscopic device to sample the oesophageal microbiota: a case-control study. *The Lancet Gastroenterology and Hepatology*, **2017**, 2, 32-42 | 18.8 | 72 |
| 158 | Clinical implications of E-cadherin associated hereditary diffuse gastric cancer. *Gut*, **2004**, 53, 775-8 | 19.2 | 72 |
| 157 | Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. *The Lancet Gastroenterology and Hepatology*, **2017**, 2, 23-31 | 18.8 | 71 |
| 156 | Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenocarcinoma in Barrett's esophagus. *Clinical Cancer Research*, **2003**, 9, 2560-6 | 12.9 | 67 |
| 155 | Comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to CDH1 mutation status. *Gastrointestinal Endoscopy*, **2018**, 87, 408-418 | 5.2 | 66 |
| 154 | Prospective cohort study assessing outcomes of patients from families fulfilling criteria for hereditary diffuse gastric cancer undergoing endoscopic surveillance. *Gastrointestinal Endoscopy*, **2014**, 80, 78-87 | 5.2 | 63 |
| 153 | A Deep Learning Framework for Predicting Response to Therapy in Cancer. *Cell Reports*, **2019**, 29, 3367-3373.e4 | 8.3 | 63 |
| 152 | Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. *Lancet, The*, **2020**, 396, 333-344 | 40 | 62 |
| 151 | DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett's esophagus. *Clinical Cancer Research*, **2013**, 19, 878-88 | 12.9 | 61 |
| 150 | Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma. *Journal of Clinical Oncology*, **2013**, 31, 1576-82 | 2.2 | 60 |
| 149 | Revised British Society of Gastroenterology recommendation on the diagnosis and management of Barrett's oesophagus with low-grade dysplasia. *Gut*, **2018**, 67, 392-393 | 19.2 | 59 |
| 148 | Cyclin A immunocytology as a risk stratification tool for Barrett's esophagus surveillance. *Clinical Cancer Research*, **2007**, 13, 659-65 | 12.9 | 59 |
| 147 | Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. *The Lancet Gastroenterology and Hepatology*, **2018**, 3, 489-498 | 18.8 | 58 |

| | | | |
|---|---|---|---|
| 146 | High-Fat Diet Accelerates Carcinogenesis in a Mouse Model of Barrett's Esophagus via Interleukin 8 and Alterations to the Gut Microbiome. *Gastroenterology*, **2019**, 157, 492-506.e2 | 13.3 | 58 |
| 145 | Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma. *British Journal of Surgery*, **2017**, 104, 1816-1828 | 5.3 | 55 |
| 144 | Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation?. *Gut*, **2005**, 54 Suppl 1, i21-6 | 19.2 | 55 |
| 143 | The combination of autofluorescence endoscopy and molecular biomarkers is a novel diagnostic tool for dysplasia in Barrett's oesophagus. *Gut*, **2015**, 64, 49-56 | 19.2 | 54 |
| 142 | The Evolving Genomic Landscape of Barrett's Esophagus and Esophageal Adenocarcinoma. *Gastroenterology*, **2017**, 153, 657-673.e1 | 13.3 | 53 |
| 141 | Methylation panel is a diagnostic biomarker for Barrett's oesophagus in endoscopic biopsies and non-endoscopic cytology specimens. *Gut*, **2018**, 67, 1942-1949 | 19.2 | 53 |
| 140 | Evidence for a functional role of epigenetically regulated midcluster HOXB genes in the development of Barrett esophagus. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 9077-82 | 11.5 | 51 |
| 139 | Acid modulation of HT29 cell growth and differentiation. An in vitro model for Barrett's esophagus. *Journal of Cell Science*, **1997**, 110, 663-671 | 5.3 | 51 |
| 138 | Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts. *Gastroenterology*, **2018**, 155, 1720-1728.e4 | 13.3 | 46 |
| 137 | Accuracy and Safety of the Cytosponge for Assessing Histologic Activity in Eosinophilic Esophagitis: A Two-Center Study. *American Journal of Gastroenterology*, **2017**, 112, 1538-1544 | 0.7 | 44 |
| 136 | Review article: Barrett's oesophagus, dysplasia and pharmacologic acid suppression. *Alimentary Pharmacology and Therapeutics*, **2001**, 15, 269-76 | 6.1 | 44 |
| 135 | Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants. *Gastroenterology*, **2018**, 154, 1273-1281.e3 | 13.3 | 43 |
| 134 | Barrett oesophagus. *Nature Reviews Disease Primers*, **2019**, 5, 35 | 51.1 | 42 |
| 133 | Identification and clinical implementation of biomarkers for Barrett's esophagus. *Gastroenterology*, **2012**, 142, 435-441.e2 | 13.3 | 42 |
| 132 | Screening for Barrett's Esophagus. *Gastroenterology*, **2015**, 148, 912-23 | 13.3 | 41 |
| 131 | A clinically translatable hyperspectral endoscopy (HySE) system for imaging the gastrointestinal tract. *Nature Communications*, **2019**, 10, 1902 | 17.4 | 40 |
| 130 | Range of pathologies diagnosed using a minimally invasive capsule sponge to evaluate patients with reflux symptoms. *Histopathology*, **2017**, 70, 203-210 | 7.3 | 39 |
| 129 | Safety and Acceptability of Esophageal Cytosponge Cell Collection Device in a Pooled Analysis of Data From Individual Patients. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 647-656.e1 | 6.9 | 38 |

| | | | |
|---|---|---|---|
| 128 | Genetic progression of Barrett's oesophagus to oesophageal adenocarcinoma. *British Journal of Cancer*, **2016**, 115, 403-10 | 8.7 | 36 |
| 127 | Altered sodium-hydrogen exchange activity is a mechanism for acid-induced hyperproliferation in Barrett's esophagus. *American Journal of Physiology - Renal Physiology*, **1998**, 275, G47-55 | 5.1 | 36 |
| 126 | Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining. *Pharmacology & Therapeutics*, **2019**, 203, 107395 | 13.9 | 35 |
| 125 | Body mass index, smoking, and alcohol and risks of Barrett's esophagus and esophageal adenocarcinoma: a UK prospective cohort study. *Digestive Diseases and Sciences*, **2014**, 59, 1552-9 | 4 | 34 |
| 124 | Amplification of TRIM44: pairing a prognostic target with potential therapeutic strategy. *Journal of the National Cancer Institute*, **2014**, 106, | 9.7 | 34 |
| 123 | New Screening Techniques in Barrett's Esophagus: Great Ideas or Great Practice?. *Gastroenterology*, **2018**, 154, 1594-1601 | 13.3 | 33 |
| 122 | Selection and Application of Tissue microRNAs for Nonendoscopic Diagnosis of Barrett's Esophagus. *Gastroenterology*, **2018**, 155, 771-783.e3 | 13.3 | 32 |
| 121 | Developing a nonendoscopic screening test for Barrett's esophagus. *Biomarkers in Medicine*, **2011**, 5, 397-404 | 2.3 | 32 |
| 120 | The mutational landscape of human somatic and germline cells. *Nature*, **2021**, 597, 381-386 | 50.4 | 32 |
| 119 | Genomic copy number predicts esophageal cancer years before transformation. *Nature Medicine*, **2020**, 26, 1726-1732 | 50.5 | 31 |
| 118 | Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis. *Journal of Pathology*, **2013**, 230, 118-28 | 9.4 | 30 |
| 117 | The impact of prophylactic total gastrectomy on health-related quality of life: a prospective cohort study. *Annals of Surgery*, **2014**, 260, 87-93 | 7.8 | 29 |
| 116 | Barrett's oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux. *BMC Cancer*, **2018**, 18, 784 | 4.8 | 29 |
| 115 | Open chromatin profiling identifies AP1 as a transcriptional regulator in oesophageal adenocarcinoma. *PLoS Genetics*, **2017**, 13, e1006879 | 6 | 28 |
| 114 | Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. *Carcinogenesis*, **2014**, 35, 2740-7 | 4.6 | 27 |
| 113 | Early detection of cancer.. *Science*, **2022**, 375, eaay9040 | 33.3 | 27 |
| 112 | Pilot randomized crossover study comparing the efficacy of transnasal disposable endosheath with standard endoscopy to detect Barrett's esophagus. *Endoscopy*, **2016**, 48, 110-6 | 3.4 | 25 |
| 111 | Somatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure. *Nature Genetics*, **2020**, 52, 1178-1188 | 36.3 | 25 |

| | | | |
|---|---|---|---|
| 110 | Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. *Gut*, **2017**, 66, 1739-1747 | 19.2 | 24 |
| 109 | Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma. *Nature Genetics*, **2020**, 52, 74-83 | 36.3 | 24 |
| 108 | Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data. *Gastroenterology*, **2020**, 158, 1682-1697.e1 | 13.3 | 23 |
| 107 | The Psychosocial Impact of Undergoing Prophylactic Total Gastrectomy (PTG) to Manage the Risk of Hereditary Diffuse Gastric Cancer (HDGC). *Journal of Genetic Counseling*, **2017**, 26, 752-762 | 2.5 | 21 |
| 106 | MiRNA-Related SNPs and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus: Post Genome-Wide Association Analysis in the BEACON Consortium. *PLoS ONE*, **2015**, 10, e0128617 | 3.7 | 21 |
| 105 | Gastro-esophageal reflux disease symptoms and demographic factors as a pre-screening tool for Barrett's esophagus. *PLoS ONE*, **2014**, 9, e94163 | 3.7 | 21 |
| 104 | Extensive phylogenies of human development inferred from somatic mutations. *Nature*, **2021**, 597, 387-392 | 3.4 | 21 |
| 103 | Analysis of dysplasia in patients with Barrett's esophagus based on expression pattern of 90 genes. *Gastroenterology*, **2015**, 149, 1511-1518.e5 | 13.3 | 20 |
| 102 | Autofluorescence-Directed Confocal Endomicroscopy in Combination With a Three-Biomarker Panel Can Inform Management Decisions in Barrett's Esophagus. *American Journal of Gastroenterology*, **2015**, 110, 1549-58 | 0.7 | 20 |
| 101 | Pilot study of cytological testing for oesophageal squamous cell dysplasia in a high-risk area in Northern Iran. *British Journal of Cancer*, **2014**, 111, 2235-41 | 8.7 | 20 |
| 100 | The Discovery and Validation of Biomarkers for the Diagnosis of Esophageal Squamous Dysplasia and Squamous Cell Carcinoma. *Cancer Prevention Research*, **2016**, 9, 558-66 | 3.2 | 20 |
| 99 | Mobile element insertions are frequent in oesophageal adenocarcinomas and can mislead paired-end sequencing analysis. *BMC Genomics*, **2015**, 16, 473 | 4.5 | 19 |
| 98 | Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. *Cell Reports*, **2020**, 31, 107550 | 10.6 | 19 |
| 97 | An investigation of the factors effecting high-risk individuals' decision-making about prophylactic total gastrectomy and surveillance for hereditary diffuse gastric cancer (HDGC). *Familial Cancer*, **2016**, 15, 665-76 | 3 | 19 |
| 96 | A biomarker panel predicts progression of Barrett's esophagus to esophageal adenocarcinoma. *Ecological Management and Restoration*, **2019**, 32, | 3 | 19 |
| 95 | Review article: Barrett's oesophagus and associated adenocarcinoma--a UK perspective. *Alimentary Pharmacology and Therapeutics*, **2004**, 20 Suppl 8, 45-9 | 6.1 | 18 |
| 94 | Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling. *Annals of Oncology*, **2021**, 32, 522-532 | 10.3 | 18 |
| 93 | Acceptability, Accuracy, and Safety of Disposable Transnasal Capsule Endoscopy for Barrett's Esophagus Screening. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 638-646.e1 | 6.9 | 18 |

| | | | |
|---|---|---|---|
| 92 | Molecular phenotyping reveals the identity of Barrett's esophagus and its malignant transition. *Science*, **2021**, 373, 760-767 | 33.3 | 18 |
| 91 | Biomarkers in Barrett's Esophagus: Role in Diagnosis, Risk Stratification, and Prediction of Response to Therapy. *Gastroenterology Clinics of North America*, **2015**, 44, 373-90 | 4.4 | 17 |
| 90 | Patient-specific cancer genes contribute to recurrently perturbed pathways and establish therapeutic vulnerabilities in esophageal adenocarcinoma. *Nature Communications*, **2019**, 10, 3101 | 17.4 | 17 |
| 89 | Triage-driven diagnosis of Barrett's esophagus for early detection of esophageal adenocarcinoma using deep learning. *Nature Medicine*, **2021**, 27, 833-841 | 50.5 | 17 |
| 88 | Design and validation of a near-infrared fluorescence endoscope for detection of early esophageal malignancy. *Journal of Biomedical Optics*, **2016**, 21, 84001 | 3.5 | 17 |
| 87 | Non-endoscopic immunocytological screening test for Barrett's oesophagus. *Gut*, **2007**, 56, 1033-4 | 19.2 | 16 |
| 86 | Gastroesophageal reflux GWAS identifies risk loci that also associate with subsequent severe esophageal diseases. *Nature Communications*, **2019**, 10, 4219 | 17.4 | 15 |
| 85 | Detection of early neoplasia in Barrett's esophagus using lectin-based near-infrared imaging: an ex vivo study on human tissue. *Endoscopy*, **2018**, 50, 618-625 | 3.4 | 15 |
| 84 | Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1. *Scientific Reports*, **2016**, 6, 32417 | 4.9 | 15 |
| 83 | A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy. *Genome Research*, **2017**, 27, 902-912 | 9.7 | 14 |
| 82 | Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 1598-1606.e4 | 6.9 | 14 |
| 81 | Machine learning to predict early recurrence after oesophageal cancer surgery. *British Journal of Surgery*, **2020**, 107, 1042-1052 | 5.3 | 14 |
| 80 | Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma. *Gut*, **2019**, 68, 1918-1927 | 19.2 | 13 |
| 79 | Progressive silencing of p14ARF in oesophageal adenocarcinoma. *Journal of Cellular and Molecular Medicine*, **2009**, 13, 398-409 | 5.6 | 13 |
| 78 | Screening and risk stratification for Barrett's esophagus: how to limit the clinical impact of the increasing incidence of esophageal adenocarcinoma. *Gastroenterology Clinics of North America*, **2013**, 42, 155-73 | 4.4 | 12 |
| 77 | Whole-genome sequencing of nine esophageal adenocarcinoma cell lines. *F1000Research*, **2016**, 5, 1336 | 3.6 | 12 |
| 76 | Impact of mutations in Toll-like receptor pathway genes on esophageal carcinogenesis. *PLoS Genetics*, **2017**, 13, e1006808 | 6 | 12 |
| 75 | Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence. *Nature Genetics*, **2021**, 53, 1553-1563 | 36.3 | 12 |

| | | | |
|---|---|---|---|
| 74 | Past, present and future of Barrett's oesophagus. *European Journal of Surgical Oncology*, **2017**, 43, 1148-1160 | 3.6 | 11 |
| 73 | Early detection and therapeutics. *Molecular Oncology*, **2019**, 13, 599-613 | 7.9 | 11 |
| 72 | Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction. *International Journal of Cancer*, **2019**, 145, 3389-3401 | 7.5 | 11 |
| 71 | Role of TFF3 as an adjunct in the diagnosis of Barrett's esophagus using a minimally invasive esophageal sampling device-The Cytosponge. *Diagnostic Cytopathology*, **2020**, 48, 253-264 | 1.4 | 11 |
| 70 | Alternatives to Traditional Per-Oral Endoscopy for Screening. *Gastrointestinal Endoscopy Clinics of North America*, **2017**, 27, 379-396 | 3.3 | 10 |
| 69 | Pan-cancer analysis of whole genomes reveals driver rearrangements promoted by LINE-1 retrotransposition in human tumours | | 10 |
| 68 | Polymorphisms in genes in the androgen pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. *International Journal of Cancer*, **2016**, 138, 1146-52 | 7.5 | 10 |
| 67 | Biomarkers for dysplastic Barrett's: ready for prime time?. *World Journal of Surgery*, **2015**, 39, 568-77 | 3.3 | 9 |
| 66 | Polymorphisms in Genes of Relevance for Oestrogen and Oxytocin Pathways and Risk of Barrett's Oesophagus and Oesophageal Adenocarcinoma: A Pooled Analysis from the BEACON Consortium. *PLoS ONE*, **2015**, 10, e0138738 | 3.7 | 9 |
| 65 | Testosterone concentrations in men on chronic glucocorticosteroid therapy. *Journal of the Royal College of Physicians of London*, **1997**, 31, 168-70 | | 9 |
| 64 | Big data is crucial to the early detection of cancer. *Nature Medicine*, **2020**, 26, 19-20 | 50.5 | 9 |
| 63 | Evolutionary dynamics in pre-invasive neoplasia. *Current Opinion in Systems Biology*, **2017**, 2, 1-8 | 3.2 | 8 |
| 62 | No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 2227-2235.e1 | 6.9 | 8 |
| 61 | Aneuploidy in targeted endoscopic biopsies outperforms other tissue biomarkers in the prediction of histologic progression of Barrett's oesophagus: A multi-centre prospective cohort study. *EBioMedicine*, **2020**, 56, 102765 | 8.8 | 8 |
| 60 | 1004 Radiofrequency Ablation in Barrett's Esophagus With Confirmed Low-Grade Dysplasia: Interim Results of a European Multicenter Randomized Controlled Trial (SURF). *Gastroenterology*, **2013**, 144, S-187 | 13.3 | 8 |
| 59 | Targeting care in Barrett's oesophagus. *Clinical Medicine*, **2014**, 14 Suppl 6, s78-83 | 1.9 | 8 |
| 58 | Association Between Levels of Sex Hormones and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 2701-2709.e3 | 6.9 | 8 |
| 57 | Development and validation of a risk prediction model to diagnose Barrett's oesophagus (MARK-BE): a case-control machine learning approach. *The Lancet Digital Health*, **2020**, 2, E37-E48 | 14.4 | 7 |

| | | | |
|---|---|---|---|
| 56 | The future of early cancer detection.. *Nature Medicine*, **2022**, 28, 666-677 | 50.5 | 7 |
| 55 | 54 Evaluation of a Minimally-Invasive Cytosponge Esophageal Cell Collection System in Patients With Barrett's Esophagus. *Gastroenterology*, **2015**, 148, S-16 | 13.3 | 6 |
| 54 | Genomics of Esophageal Cancer and Biomarkers for Early Detection. *Advances in Experimental Medicine and Biology*, **2016**, 908, 237-63 | 3.6 | 6 |
| 53 | Application of a multi-gene next-generation sequencing panel to a non-invasive oesophageal cell-sampling device to diagnose dysplastic Barrett's oesophagus. *Journal of Pathology: Clinical Research*, **2017**, 3, 258-267 | 5.3 | 6 |
| 52 | 958 Time: A Prospective Study Combining Endoscopic Trimodal Imaging and Molecular Endpoints to Improve Risk Stratification in Barrett's Esophagus. *Gastroenterology*, **2012**, 142, S-165 | 13.3 | 6 |
| 51 | Use of Cytosponge as a triaging tool to upper gastrointestinal endoscopy during the COVID-19 pandemic. *The Lancet Gastroenterology and Hepatology*, **2020**, 5, 805-806 | 18.8 | 6 |
| 50 | Chromosomal copy number heterogeneity predicts survival rates across cancers. *Nature Communications*, **2021**, 12, 3188 | 17.4 | 6 |
| 49 | Evolution and progression of Barrett's oesophagus to oesophageal cancer. *Nature Reviews Cancer*, **2021**, 21, 731-741 | 31.3 | 6 |
| 48 | Combining simple patient-oriented tests with state-of-the-art molecular diagnostics for early diagnosis of cancer. *United European Gastroenterology Journal*, **2015**, 3, 226-9 | 5.3 | 5 |
| 47 | Endogenous aldehyde accumulation generates genotoxicity and exhaled biomarkers in esophageal adenocarcinoma. *Nature Communications*, **2021**, 12, 1454 | 17.4 | 5 |
| 46 | Minimally invasive esophageal sponge cytology sampling is feasible in a Tanzanian community setting. *International Journal of Cancer*, **2021**, 148, 1208-1218 | 7.5 | 5 |
| 45 | Shared Genetic Etiology of Obesity-Related Traits and Barrett's Esophagus/Adenocarcinoma: Insights from Genome-Wide Association Studies. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 427-433 | 4 | 4 |
| 44 | Screening for Barrett's Esophagus: Are New High-Volume Methods Feasible?. *Digestive Diseases and Sciences*, **2018**, 63, 2105-2114 | 4 | 4 |
| 43 | Limitations of Heartburn and Other Societies' Criteria in Barrett's Screening for Detecting De Novo Esophageal Adenocarcinoma. *Clinical Gastroenterology and Hepatology*, **2021**, | 6.9 | 4 |
| 42 | Comparison of Phenotypes and Risk Factors for Esophageal Adenocarcinoma at Present vs Prior Decades. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 2710-2716.e1 | 6.9 | 4 |
| 41 | Sex-Specific Genetic Associations for Barrett's Esophagus and Esophageal Adenocarcinoma. *Gastroenterology*, **2020**, 159, 2065-2076.e1 | 13.3 | 4 |
| 40 | Hereditary Diffuse Gastric Cancer: Approaches to Screening, Surveillance, and Treatment. *Annual Review of Medicine*, **2021**, 72, 263-280 | 17.4 | 4 |
| 39 | High-risk individuals' perceptions of reproductive genetic testing for CDH1 mutations. *Familial Cancer*, **2017**, 16, 531-535 | 3 | 3 |

| | | | |
|---|---|---|---|
| 38 | The mutREAD method detects mutational signatures from low quantities of cancer DNA. *Nature Communications*, **2020**, 11, 3166 | 17.4 | 3 |
| 37 | Evidence that polyploidy in esophageal adenocarcinoma originates from mitotic slippage caused by defective chromosome attachments. *Cell Death and Differentiation*, **2021**, 28, 2179-2193 | 12.7 | 3 |
| 36 | Feasibility of combined screening for upper gastrointestinal adenocarcinoma risk by serology and Cytosponge testing: the SUGAR study. *Journal of Clinical Pathology*, **2019**, 72, 825-829 | 3.9 | 3 |
| 35 | Single-bite versus double-bite technique for mapping biopsies during endoscopic surveillance for hereditary diffuse gastric cancer: a single-center, randomized trial. *Endoscopy*, **2021**, 53, 246-253 | 3.4 | 3 |
| 34 | Progress in Screening for Barrett's Esophagus: Beyond Standard Upper Endoscopy. *Gastrointestinal Endoscopy Clinics of North America*, **2021**, 31, 43-58 | 3.3 | 3 |
| 33 | Early Diagnosis of Gastroesophageal Cancers and the Cytosponge: A Work in Progress. *Cellular and Molecular Gastroenterology and Hepatology*, **2017**, 4, 447 | 7.9 | 2 |
| 32 | Ingested asbestos in filtered beer, in addition to occupational exposure, as a causative factor in oesophageal adenocarcinoma. *British Journal of Cancer*, **2019**, 120, 1099-1104 | 8.7 | 2 |
| 31 | Barrett's oesophagus and oesophageal adenocarcinoma. *Medicine*, **2019**, 47, 275-285 | 0.6 | 2 |
| 30 | Conference report: improving outcomes for gastrointestinal cancer in the UK. *Frontline Gastroenterology*, **2018**, 9, 49-61 | 2.6 | 2 |
| 29 | The landscape of selection in 551 Esophageal Adenocarcinomas defines genomic biomarkers for the clinic | | 2 |
| 28 | Time to Challenge Current Strategies for Detection of Barrett's Esophagus and Esophageal Adenocarcinoma. *Digestive Diseases and Sciences*, **2020**, 65, 18-21 | 4 | 2 |
| 27 | Serial Circulating Tumor DNA Detection Using a Personalized, Tumor-Informed Assay in Esophageal Adenocarcinoma Patients Following Resection. *Gastroenterology*, **2021**, 161, 1705-1708.e2 | 13.3 | 2 |
| 26 | The risk of neoplasia in patients with Barrett's esophagus indefinite for dysplasia: a multicenter cohort study. *Gastrointestinal Endoscopy*, **2021**, 94, 263-270.e2 | 5.2 | 2 |
| 25 | Multi-omic cross-sectional cohort study of pre-malignant Barrett's esophagus reveals early structural variation and retrotransposon activity.. *Nature Communications*, **2022**, 13, 1407 | 17.4 | 2 |
| 24 | Impact of Barrett oesophagus diagnoses and endoscopies on oesophageal cancer survival in the UK: A cohort study.. *Cancer Medicine*, **2021**, | 4.8 | 2 |
| 23 | Women in hospital medicine: career choices and opportunities. *British Journal of Hospital Medicine*, **2001**, 62, 778-9 | | 1 |
| 22 | Screening for Barrett Esophagus With a Nonendoscopic Sponge Capsule. *Gastroenterology and Hepatology*, **2015**, 11, 623-5 | 0.7 | 1 |
| 21 | Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot.. *Lancet Oncology, The*, **2022**, | 21.7 | 1 |

| | | | |
|---|---|---|---|
| 20 | Patient-specific detection of cancer genes reveals recurrently perturbed processes in esophageal adenocarcinoma | | 1 |
| 19 | Extensive phylogenies of human development reveal variable embryonic patterns | | 1 |
| 18 | Genomic instability signals offer diagnostic possibility in early cancer detection. *Trends in Genetics*, **2021**, 37, 966-972 | 8.5 | 1 |
| 17 | A crosssectional analysis of Facebook comments to study public perception of a new diagnostic test called the Cytosponge. *Ecological Management and Restoration*, **2019**, 32, | 3 | 1 |
| 16 | Practical early cancer detection: distinguishing stable from unstable genomes in pre-cancerous tissues. *British Journal of Cancer*, **2021**, 124, 683-685 | 8.7 | 1 |
| 15 | Utility and Cost-Effectiveness of a Nonendoscopic Approach to Barrett's Esophagus Surveillance After Endoscopic Therapy. *Clinical Gastroenterology and Hepatology*, **2021**, | 6.9 | 1 |
| 14 | Randomized Controlled Trial of the Gastrin/CCK Receptor Antagonist Netazepide in Patients with Barrett's Esophagus. *Cancer Prevention Research*, **2021**, 14, 675-682 | 3.2 | 1 |
| 13 | Organ-preserving approaches in oesophageal cancer. *Lancet Oncology, The*, **2018**, 19, 858-859 | 21.7 | 1 |
| 12 | Patient-reported experiences and views on the Cytosponge test: a mixed-methods analysis from the BEST3 trial.. *BMJ Open*, **2022**, 12, e054258 | 3 | 1 |
| 11 | Rearrangement processes and structural variations show evidence of selection in oesophageal adenocarcinomas.. *Communications Biology*, **2022**, 5, 335 | 6.7 | 1 |
| 10 | Screening for Barrett's Oesophagus: Are We Ready for it?. *Current Treatment Options in Gastroenterology*, **2021**, 19, 1-16 | 2.5 | 0 |
| 9 | Economic evaluation of Cytosponge -trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data. *EClinicalMedicine*, **2021**, 37, 100969 | 11.3 | 0 |
| 8 | Leadership roles for women in gastroenterology: New initiatives for the new generation of gastroenterologists. *United European Gastroenterology Journal*, **2016**, 4, 815 | 5.3 | 0 |
| 7 | Medicine is the ultimate personalised technology. *BMJ, The*, **2017**, 357, j1750 | 5.9 | |
| 6 | Computational pathology aids derivation of microRNA biomarker signals from Cytosponge samples.. *EBioMedicine*, **2022**, 76, 103814 | 8.8 | |
| 5 | National clinician scientist posts. *BMJ, The*, **2002**, 325, S101 | 5.9 | |
| 4 | Genetics and Biomarkers in Barrett Esophagus and Esophageal Adenocarcinoma **2016**, 37-60 | | |
| 3 | The utility of a methylation panel in the assessment of clinical response to radiofrequency ablation for Barrett's esophagus. *EBioMedicine*, **2020**, 58, 102877 | 8.8 | |

| | | |
|---|---|---|
| 2 | Endoscopic tumour morphology impacts survival in adenocarcinoma of the oesophagus. *European Journal of Surgical Oncology*, **2020**, 46, 2257-2261 | 3.6 |
| 1 | DNA Methylation Biomarkers for the Diagnosis of Barrett's Oesophagus. *American Journal of Gastroenterology*, **2018**, 113, 1722 | 0.7 |